Letting the mantle out of the bag.
clinical guidelines
mantle cell lymphoma
non-Hodgkin's lymphomas
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
25 Oct 2023
25 Oct 2023
Historique:
received:
22
09
2023
accepted:
23
09
2023
medline:
26
10
2023
pubmed:
26
10
2023
entrez:
26
10
2023
Statut:
aheadofprint
Résumé
Mantle cell lymphoma is a rare disease that attracts the curiosity of clinicians and scientists due to its heterogeneous clinical behaviour, that can vary from indolent forms to the most aggressive presentations among non-Hodgkin lymphomas. The report by Eyre and colleagues describes the current treatment strategies available in most countries, and offers insights to clinicians for several intriguing difficult-to-treat scenarios. Commentary on: Eyre et al. Diagnosis and management of mantle cell lymphoma: a British Society for Haematology Guideline. Br J Haematol 2023 (Online ahead of print). doi: 10.1111/bjh.19131.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Eyre T, Bishton MJ, McCulloch R, O’Reilly M, Sanderson R, Menon G, et al. Diagnosis and management of mantle cell lymphoma: a British Society for Haematology Guideline. Br J Haematol. 2023. https://doi.org/10.1111/bjh.19131
Weisenburger DD, Nathwani BN, Diamond LW, Winberg CD, Rappaport H. Malignant lymphoma, intermediate lymphocytic type: a clinicopathologic study of 42 cases. Cancer. 1981;48:1415-1425.
Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122(10):3416-3423.
Visco C, di Rocco A, Evangelista A, Quaglia FM, Tisi MC, Morello L, et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia. 2021;35(3):787-795.
Rusconi C, Cheah CY, Eyre TA, Tucker D, Klener P, Giné E, et al. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. Blood. 2022;140(17):1907-1916.
Villa D, Jiang A, Visco C, Crosbie N, McCulloch R, Buege MJ, et al. Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma. Blood Adv. 2023;7(16):4576-4585.
Scheubeck G, Jiang L, Hermine O, Kluin-Nelemans HC, Schmidt C, Unterhalt M, et al. Clinical outcome of mantle cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression). Leukemia. 2023;37(9):1887-1894.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331-1342.
Rampotas A, Wilson MR, Lomas O, Denny N, Leary H, Ferguson G, et al. Treatment patterns and outcomes of unfit and elderly patients with mantle cell lymphoma unfit for standard immunochemotherapy: a UK and Ireland analysis. Br J Haematol. 2021;194(2):365-377.